"But I do agree that if there is a robust immune response in Phase II trials, Professor Frazer has won the global research race to cure HSV-1. I reckon he's got this. :)"
----
HSV-2? He's not exactly running his own race.
Genocea Biosciences is ahead by a year. Vical just commenced recruiting for their Phase 1/2 in December, with an end date of 2015 so they will be level with Frazer by the time he gets his 2a completed.
If you look at Fiercebiotech, big Pharma have no probs entering into billion dollar deals for pre-clinical programs for all types of indications. It's illustrative that none of the big boys have done big deals in this space and on the above players despite some promising results thus far.
By the way I'm surprised Bill Halford gets any work done on his vaccine given how often he responds to people on his blog.
updated ballieu report - target range 25-55c, page-46
Add AVR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$17.05 |
Change
-0.300(1.73%) |
Mkt cap ! $327.7M | |||
| Open | High | Low | Value | Volume |
| $17.00 | $17.44 | $16.95 | $184.6K | 10.84K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 191 | $17.15 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $17.50 | 500 | 1 |
View Market Depth
| Last trade - 15.59pm 19/07/2024 (20 minute delay) ? |
| AVR (ASX) Chart |